stoxline Quote Chart Rank Option Currency Glossary
  
4D Molecular Therapeutics, Inc. (FDMT)
4.58  -0.735 (-13.83%)    02-11 16:00
Open: 5.19
High: 5.2676
Volume: 1,239,453
  
Pre. Close: 5.315
Low: 4.57
Market Cap: 212(M)
Technical analysis
2025-02-11 4:45:19 PM
Short term     
Mid term     
Targets 6-month :  6.96 1-year :  8.07
Resists First :  5.96 Second :  6.9
Pivot price 5.42
Supports First :  4.42 Second :  3.68
MAs MA(5) :  5.67 MA(20) :  5.25
MA(100) :  7.45 MA(250) :  16.87
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  34.6 D(3) :  52.4
RSI RSI(14): 37.2
52-week High :  36.25 Low :  4.42
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ FDMT ] has closed above bottom band by 15.7%. Bollinger Bands are 8.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.27 - 5.31 5.31 - 5.33
Low: 4.5 - 4.54 4.54 - 4.56
Close: 4.53 - 4.59 4.59 - 4.62
Company Description

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Headline News

Mon, 10 Feb 2025
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study - Benzinga

Mon, 10 Feb 2025
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts - Benzinga

Sat, 08 Feb 2025
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program - Yahoo Finance

Fri, 24 Jan 2025
FDMT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

Tue, 21 Jan 2025
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT - PR Newswire

Mon, 13 Jan 2025
4D Molecular Therapeutics' SWOT analysis: gene therapy stock faces pivotal year - Investing.com

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 4.623e+007 (%)
Held by Institutions 2.528e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -9.708e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.85
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 704 %
Return on Equity (ttm) 400 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -34.97
Sales Per Share -8.6
EBITDA (p.s.) 0
Qtrly Earnings Growth -1.6369e+008 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -1.61
Price to Sales -0.54
Price to Cash Flow 0
Stock Dividends
Dividend 7.67e+006
Forward Dividend 8.92e+006
Dividend Yield 167467000%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android